(R)-BEL is an irreversible, chiral, mechanism-based inhibitor of iPLA2γ (IC50 ~ 0.6 μM). Unlike (S)-BEL, (R)-BEL does not inhibit iPLA2β except at high doses (20-30 μM).
1. Balsinde, J., et al., 1999. Regulation and inhibition of phospholipase A2. Annual review of pharmacology and toxicology. 39(): 175-89. PMID: 10331081
2. Jenkins, Christopher M., et al., 2002. Identification of calcium-independent phospholipase A2 (iPLA2) beta, and not iPLA2gamma, as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA2s. The Journal of biological chemistry. 277(36): 32807-14. PMID: 12089145
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2021 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.